BioPharmSignal logoBioPharmSignal

Biotech News

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Aziyo Biologics (AZYO)Aziyo BiologicsCommercial

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia’s attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting

Related news

AZYOAziyo Biologics2026-07-16 20:05 EST

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

AZYOAziyo Biologics2026-03-02 13:00 EST

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

View all latest news

Aziyo Biologics

Drug-Eluting Biomatrix Company Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site. Antibiotic-Eluting Platform The company's biomatrix technology incorporates antibiotics into a biologic scaffold. The platform was first...

Recent company news

AZYOAziyo Biologics2026-08-18 12:00 EST

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

AZYOAziyo Biologics2026-08-13 20:10 EST

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

AZYOAziyo Biologics2026-08-13 20:05 EST

Elutia Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41x Launch in $1.5 Billion Plastic and Reconstructive Surgery Market

AZYOAziyo Biologics2026-07-31 12:00 EST

Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

AZYOAziyo Biologics2026-07-16 20:05 EST

Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States